| 臺大學術典藏 |
2021-06-02T05:43:54Z |
Mana-Hox displays anticancer activity against prostate cancer cells through tubulin depolymerization and DNA damage stress
|
Hsiao C.-J.; Ho Y.-F.; Hsu J.T.-A.; Chang W.-L.; Chen Y.-C.; Shen Y.-C.; Lyu P.-C.; JIH-HWA GUH |
| 臺大學術典藏 |
2021-06-02T05:43:51Z |
2-Phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimidazole derivative, inhibits growth of human prostate cancer cells by affecting tubulin and c-Jun N-terminal kinase
|
Chang W.-L.; Chang C.-S.; Chiang P.-C.; Ho Y.-F.; Liu J.-F.; Chang K.-W.; JIH-HWA GUH |
| 臺大學術典藏 |
2021-06-02T05:43:49Z |
Costunolide induces apoptosis through nuclear calcium2+ overload and DNA damage response in human prostate cancer
|
Hsu J.-L.; Pan S.-L.; Ho Y.-F.; Hwang T.-L.; Kung F.-L.; JIH-HWA GUH |
| 臺大學術典藏 |
2021-06-02T05:43:47Z |
Paclitaxel induces apoptosis through activation of nuclear protein kinase C-δ and subsequent activation of Golgi associated Cdk1 in human hormone refractory prostate cancer
|
Lu P.-H.; Yu C.-C.; Chiang P.-C.; Chen Y.-C.; Ho Y.-F.; Kung F.-L.; JIH-HWA GUH |
| 臺大學術典藏 |
2021-06-02T05:43:45Z |
Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I-DNA cleavage complexes in a PKCδ-independent pathway
|
Hsu J.-L.; Ho Y.-F.; Li T.-K.; Chen C.-S.; Hsu L.-C.; JIH-HWA GUH |
| 臺大學術典藏 |
2021-06-02T05:43:45Z |
Pim-1 knockdown potentiates paclitaxel-induced apoptosis in human hormone-refractory prostate cancers through inhibition of NHEJ DNA repair
|
Hsu J.-L.; Leong P.-K.; Ho Y.-F.; Hsu L.-C.; Lu P.-H.; Chen C.-S.; JIH-HWA GUH |
| 臺大學術典藏 |
2021-06-02T05:43:44Z |
Ardisianone, a natural benzoquinone, efficiently induces apoptosis in human hormone-refractory prostate cancers through mitochondrial damage stress and survivin downregulation
|
Yu C.-C.; Wu P.-J.; Hsu J.-L.; Ho Y.-F.; Hsu L.-C.; Chang Y.-J.; Chang H.-S.; Chen I.-S.; JIH-HWA GUH |
| 臺大學術典藏 |
2021-06-02T05:43:42Z |
Terfenadine induces anti-proliferative and apoptotic activities in human hormone-refractory prostate cancer through histamine receptor-independent Mcl-1 cleavage and Bak up-regulation
|
Wang W.-T.; Chen Y.-H.; Hsu J.-L.; Leu W.-J.; Yu C.-C.; Chan S.-H.; Ho Y.-F.; Hsu L.-C.; JIH-HWA GUH |
| 臺大學術典藏 |
2021-06-02T05:43:40Z |
A unique amidoanthraquinone derivative displays antiproliferative activity against human hormone-refractory metastatic prostate cancers through activation of LKB1-AMPK-mTOR signaling pathway
|
Hsu J.-L.; Liu S.-P.; Lee C.-C.; Hsu L.-C.; Ho Y.-F.; Huang H.-S.; JIH-HWA GUH |
| 臺大學術典藏 |
2021-03-12T07:59:00Z |
The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese
|
Kai Hsiang Stanley Chen; Wu, R.M.; Cheng, C.W.; Lu, S.L.; Shan, D.E.; Ho, Y.F.; Chern, H.D. |
| 臺大學術典藏 |
2021-03-12T07:59:00Z |
Genetic polymorphism of the CYP2E1 gene and susceptibility to Parkinson's disease in Taiwanese
|
Kai Hsiang Stanley Chen; Wu, R.M.; Cheng, C.W.; Chen, K.H.; Shan, D.E.; Kuo, J.W.; Ho, Y.F.; Chern, H.D. |
| 臺大學術典藏 |
2021-02-02T08:29:56Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; BOR-RU LIN; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-02-02T02:22:37Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; MING-SHIANG WU; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-02-02T00:47:06Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.;Hsu C.-H.;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chen C.-A.;Lai M.-K.;Yeong-Shiau Pu;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Hsieh C.-Y.; Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; YEONG-SHIAU PU; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-01-29T03:17:24Z |
A unique amidoanthraquinone derivative displays antiproliferative activity against human hormone-refractory metastatic prostate cancers through activation of LKB1-AMPK-mTOR signaling pathway
|
Hsu J.-L.;Shih-Ping Liu;Lee C.-C.;Hsu L.-C.;Ho Y.-F.;Huang H.-S.;Guh J.-H.; Hsu J.-L.; SHIH-PING LIU; Lee C.-C.; Hsu L.-C.; Ho Y.-F.; Huang H.-S.; Guh J.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:42Z |
Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers
|
Ho Y.-F.;Lu W.-C.;Chen R.R.-L.;Cheng A.-L.;Kun-Huei Yeh; Ho Y.-F.; Lu W.-C.; Chen R.R.-L.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-07T06:08:42Z |
Comedication with interacting drugs predisposes amiodarone users in cardiac and surgical intensive care units to acute liver injury: A retrospective analysis
|
Ho Y.-F.;Chou H.-Y.;Chu J.-S.;Ping-Ing Lee; Ho Y.-F.; Chou H.-Y.; Chu J.-S.; PING-ING LEE |
| 臺大學術典藏 |
2021-01-07T06:08:39Z |
The Advantages and Challenges of Using Real-World Data for Patient Care
|
Ho Y.-F.;Hu F.-C.;Ping-Ing Lee; Ho Y.-F.; Hu F.-C.; PING-ING LEE |
| 臺大學術典藏 |
2020-12-24T07:20:06Z |
Does Chinese herb nephropathy account for the high incidence of end-stage renal disease in Taiwan?
|
Lin Wu F.-L.; Chen Y.-M.; TAI-SHUAN LAI; Shen L.-J.; Ho Y.-F.; Lee Y.-T.; Wu M.-S.; Lin S.-L.; Wu K.-D. |
| 臺大學術典藏 |
2020-12-24T06:30:32Z |
Does Chinese herb nephropathy account for the high incidence of end-stage renal disease in Taiwan?
|
Wu K.-D.; Lin S.-L.; Wu M.-S.; Lee Y.-T.; Ho Y.-F.; Shen L.-J.; Lai T.-S.; YUNG-MING CHEN; Lin Wu F.-L. |
| 臺大學術典藏 |
2020-11-27T08:14:40Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.;Hsu C.-H.;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chen C.-A.;Lai M.-K.;Pu Y.-S.;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Chang-Yao Hsieh; Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; CHANG-YAO HSIEH |
| 臺大學術典藏 |
2020-11-02T02:05:31Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Hsieh C.-Y.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; MING-SHIANG WU; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Ho Y.-F.; Hsu M.-M.; Lin J.-K.; Hsu C.-H.; Chen A.-L. |
| 臺大學術典藏 |
2020-07-07T05:19:28Z |
Nephrotoxic polypharmacy and risk of contrast medium-induced nephropathy in hospitalized patients undergoing contrast-enhanced CT
|
Hsieh K.-L.; Kung F.-L.; Wu F.-L.L.; Hsieh L.-L.; Chou H.; SHYH-JYE CHEN; Ho Y.-F.;Hsieh K.-L.;Kung F.-L.;Wu F.-L.L.;Hsieh L.-L.;Chou H.;Shyh-Jye Chen; Ho Y.-F. |
| 臺大學術典藏 |
2020-05-04T08:02:28Z |
Scheduling of variable-time jobs for distributed systems with heterogeneous processor cardinality
|
Wu, J.-J.; Chang, H.-J.; Ho, Y.-F.; Liu, P.; PANGFENG LIU |
| 臺大學術典藏 |
2020-04-28T07:25:39Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y.; Lin B.-R.; Lin J.-T.; Ko J.-Y.; She T.-S.; Ho Y.-F.; CHIH-HUNG HSU; Lin J.-K.; Hsu M.-M.; Chen A.-L.; Chen A.-L.;Chih-Hung Hsu;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chen C.-A.;Lai M.-K.;Pu Y.-S.;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Hsieh C.-Y. |
